Moderna price jumps — what’s behind today’s move (January 13)

Traders Union
All News
Financial News
Moderna Surges 15.51% Today on Gains

Highlights

Moderna projects approximately $1.9 billion in revenue for 2025 and expects operating expenses of $5.0–$5.2 billion, ending 2025 with about $8.1 billion in cash.
Regulatory submissions for Moderna’s mRNA-1010 flu vaccine and combined flu/COVID vaccine are progressing, with late-stage cancer vaccine trials ongoing in partnership with Merck.
The FDA selected a Moderna rare disease therapeutic for a pilot program, reflecting progress in the company's broader pipeline.

Pipeline advances and cash reserves fuel optimism amid expense shift

Moderna has projected approximately $1.9 billion in revenue for 2025 and improved its operating expense guidance to the $5.0–$5.2 billion range, while ending the year with about $8.1 billion in cash. The company continues to advance its pipeline, with regulatory submissions for its mRNA-1010 flu vaccine and combined flu/COVID vaccine moving forward and late-stage trials underway for its cancer vaccine in partnership with Merck. Moderna also reported progress on a rare disease therapeutic selected by the FDA for a pilot program.

Anton Kharitonov, expert at Traders Union, sees recent gains for Moderna as technically strong but warns of overextension. He notes the rally is driven by both positive news flow and bullish momentum, yet lingering overbought signals could dampen future upside. The company's guidance upgrades and cash position are positives, but elevated operating expenses and reliance on clinical trial outcomes heighten risk. Kharitonov believes investor sentiment could reverse sharply if breakthrough pipeline products disappoint. "Despite this surge, I advise caution — a correction may be imminent if the price fails to hold above support."

Viktoras Karapetjanc, expert at Traders Union, emphasizes that Moderna's sustained cash reserves and advancing vaccine pipeline underpin a constructive long-term picture. He states that market optimism is well-placed as fundamental and sentiment trends remain supportive. Karapetjanc is confident further growth is likely, especially if the company’s cancer and rare disease program deliver additional milestones. "The bullish structure remains firmly intact — I expect the market to reward consistent progress with continued upside."

Jainam Mehta, market strategist, views the technical setup as momentum-driven but notes that volatility may soon create contrarian opportunities. He recognizes robust price action above all major moving averages, but sees the risk of a sharp pullback if overbought signals persist. Mehta suggests tactical traders watch for a potential breakout above $42.37 or a reversal from stretched levels. "This setup calls for flexibility — I’d monitor for both breakout continuation and a possible countertrend fade near the highs."

Overbought signals emerge as momentum confirms intraday rally strength

Momentum indicators on the daily chart are firmly positive, with MACD and ADX confirming a bullish trend. However, oscillators such as Stoch RSI and CCI highlight the risk of overbought conditions, as does the very high BBP, signaling strong buyer dominance intraday. The Awesome Oscillator supports the bullish direction. After opening higher at $34.40, MRNA has rallied sharply, currently up $5.25 (15.51%) from the previous close, with a clear gap up and the price trading near the day’s high, indicating high volatility and persistent strength throughout the session. While momentum and price action both confirm bullishness, the presence of overbought signals introduces some caution regarding further near-term upside.

Previously it was reported that MRNA's bullish technical structure was supported by a price trend above key moving averages and a positive daily MACD, while momentum oscillators like RSI and CCI signaled overbought conditions. Intraday volatility persisted as the stock slid 5.66% to $33.86, closing near session lows and highlighting short-term pressure despite constructive longer-term momentum.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.